707 reports of this reaction
4.5% of all FAM TRASTUZUMAB DERUXTECAN NXKI reports
#5 most reported adverse reaction
OFF LABEL USE is the #5 most commonly reported adverse reaction for FAM TRASTUZUMAB DERUXTECAN NXKI, manufactured by Daiichi Sankyo Inc.. There are 707 FDA adverse event reports linking FAM TRASTUZUMAB DERUXTECAN NXKI to OFF LABEL USE. This represents approximately 4.5% of all 15,771 adverse event reports for this drug.
Patients taking FAM TRASTUZUMAB DERUXTECAN NXKI who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is moderately reported among FAM TRASTUZUMAB DERUXTECAN NXKI users, representing a notable but not dominant share of adverse events.
In addition to off label use, the following adverse reactions have been reported for FAM TRASTUZUMAB DERUXTECAN NXKI:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 707 FDA reports for FAM TRASTUZUMAB DERUXTECAN NXKI. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 4.5% of all adverse event reports for FAM TRASTUZUMAB DERUXTECAN NXKI, making it a notable side effect.
If you experience off label use while taking FAM TRASTUZUMAB DERUXTECAN NXKI, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.